LOXL4 and urinary bladder cancer: The mechanism by which miR-193a-3p enhanced drug resistance was shown to be the inhibition of Serine/arginine-rich splicing factor 2 (SRSF2) and lysyl oxidase-like 4 (LOXL4) expression in bladder cancer cells (Deng et al., 2014).